Industry update Despite mixed Q1 results, Aurora soars on Biden victory Company stock has surged more than 150% since Nov. 5, even while reporting declining Canadian weed sales Jared GnamNovember 9, 2020
Canada Canopy celebrates rising Canadian sales and Biden win The Ontario-based super-producer saw Q2 sales grow 23% while it adjusted its US expansion strategy for a Democrat in the White House Jared GnamNovember 9, 2020
Canada Talking pain and cannabis with Canopy’s head of medicine: Q&A As part of National Pain Awareness Week, Canopy's chief medical officer discusses how Canadians are navigating chronic pain with weed Nick LabaNovember 7, 2020
Psychedelics Psilocybin therapy 4 times more effective than antidepressants: study A first-of-its-kind clinical trial shows a dramatic drop in depression in over half of patients who received a synthetic version of the compound Jared GnamNovember 6, 2020
Enforcement Decriminalizing drugs in Oregon ends thousands of arrests, expands treatment Following a successful ballot measure this week, Oregon became the first state to downgrade simple possession to a civil offence Suzannah WeissNovember 6, 2020
Canada What to expect from the industry-led Cannabis Act review Nov. 11, the Canadian Chamber of Commerce’s National Cannabis Working Group begins a series of roundtables on regulatory reforms that would benefit the sector Nicholas SokićNovember 6, 2020
Industry update Cronos stock pops despite rising losses While third quarter revenues climbed 15% sequentially, the Ontario producer continues to pile up operating losses Jared GnamNovember 5, 2020
Analysis Analyst lukewarm on Aphria’s US$300M SweetWater acquisition Chris Damas of BCMI is skeptical the craft beer deal will give the Canadian producer a strong foothold in the US Jared GnamNovember 5, 2020
Analysis Bi-partisan cannabis ballot sweep could trigger green wave in neighbour states With NJ to set up its adult market this year, states like NY, CT, PA and MD will follow, says Chris Lindsey of the... Jared GnamNovember 4, 2020
Industry update GW Pharma shares soar 21% on rising revenues The cannabinoid drugmaker also launched a Phase 3 trial for a multiple sclerosis treatment Jared GnamNovember 3, 2020